JPWO2020041520A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041520A5 JPWO2020041520A5 JP2021502951A JP2021502951A JPWO2020041520A5 JP WO2020041520 A5 JPWO2020041520 A5 JP WO2020041520A5 JP 2021502951 A JP2021502951 A JP 2021502951A JP 2021502951 A JP2021502951 A JP 2021502951A JP WO2020041520 A5 JPWO2020041520 A5 JP WO2020041520A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 53
- 102000036639 antigens Human genes 0.000 claims description 53
- 108091007433 antigens Proteins 0.000 claims description 53
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 38
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024083589A JP7793679B2 (ja) | 2018-08-21 | 2024-05-22 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720234P | 2018-08-21 | 2018-08-21 | |
| US62/720,234 | 2018-08-21 | ||
| PCT/US2019/047573 WO2020041520A1 (en) | 2018-08-21 | 2019-08-21 | Monoclonal antibodies against human tim-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083589A Division JP7793679B2 (ja) | 2018-08-21 | 2024-05-22 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534735A JP2021534735A (ja) | 2021-12-16 |
| JPWO2020041520A5 true JPWO2020041520A5 (https=) | 2022-07-27 |
| JP2021534735A5 JP2021534735A5 (https=) | 2022-07-27 |
| JP7543247B2 JP7543247B2 (ja) | 2024-09-02 |
Family
ID=69591459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502951A Active JP7543247B2 (ja) | 2018-08-21 | 2019-08-21 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
| JP2024083589A Active JP7793679B2 (ja) | 2018-08-21 | 2024-05-22 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024083589A Active JP7793679B2 (ja) | 2018-08-21 | 2024-05-22 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12134645B2 (https=) |
| EP (1) | EP3841125A4 (https=) |
| JP (2) | JP7543247B2 (https=) |
| KR (1) | KR102917630B1 (https=) |
| CN (3) | CN118667020A (https=) |
| AU (1) | AU2019325558A1 (https=) |
| BR (1) | BR112021003018A2 (https=) |
| CA (1) | CA3108879A1 (https=) |
| IL (1) | IL280757A (https=) |
| MX (1) | MX2020013428A (https=) |
| NZ (1) | NZ770219A (https=) |
| SG (1) | SG11202012148RA (https=) |
| WO (1) | WO2020041520A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12134645B2 (en) * | 2018-08-21 | 2024-11-05 | Albert Einstein College Of Medicine | Monoclonal antibodies against human tim-3 |
| WO2021175191A1 (zh) * | 2020-03-02 | 2021-09-10 | 信达生物制药(苏州)有限公司 | 抗tim-3抗体及其用途 |
| CN117377692A (zh) | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | Tim-3-靶向抗体及其用途 |
| WO2023174278A1 (zh) | 2022-03-14 | 2023-09-21 | 正大天晴药业集团南京顺欣制药有限公司 | 抗tim-3抗体与去甲基化药物的药物组合 |
| WO2023174408A1 (zh) * | 2022-03-18 | 2023-09-21 | 正大天晴药业集团南京顺欣制药有限公司 | 抗tim-3抗体与抗pd-l1抗体的药物组合 |
| US20250282873A1 (en) | 2022-05-13 | 2025-09-11 | Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group | Drug combination of anti-tim-3 antibody and anti-pd-1 antibody |
| CN119789867A (zh) * | 2022-09-06 | 2025-04-08 | 正大天晴药业集团股份有限公司 | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |
| CN120752053A (zh) * | 2023-03-03 | 2025-10-03 | 正大天晴药业集团南京顺欣制药有限公司 | 含抗tim-3抗体的药物组合 |
| WO2025056005A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 抗tim-3抗体的药物组合物及用途 |
| WO2025056014A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| MXPA06003686A (es) | 2003-10-03 | 2007-03-01 | Brigham & Womens Hospital | Ligandos tim-3 y sus metodos. |
| EP1682890A2 (en) * | 2003-11-13 | 2006-07-26 | Genentech, Inc. | Screening assays and methods of tumor treatment |
| EP1865058B1 (en) | 2005-03-31 | 2011-01-12 | Biomedics Inc. | Anti-cd-20 monoclonal antibody |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| CN101778867A (zh) | 2007-06-08 | 2010-07-14 | 地中海大学 | 用于治疗胰腺肿瘤的组合物和方法 |
| WO2011100538A1 (en) | 2010-02-11 | 2011-08-18 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-cd200 antibodies |
| WO2011155607A1 (ja) * | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| US9321833B2 (en) | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| PE20160870A1 (es) | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
| EP3099717B1 (en) * | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| PT3215532T (pt) * | 2014-11-06 | 2019-12-18 | Hoffmann La Roche | Anticorpos anti-tim3 e métodos de utilização |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA2978892A1 (en) * | 2015-03-06 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| TN2018000333A1 (en) * | 2016-04-12 | 2020-01-16 | Symphogen As | Anti-tim-3 antibodies and compositions |
| MY200602A (en) | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| US11203637B2 (en) * | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| US12134645B2 (en) | 2018-08-21 | 2024-11-05 | Albert Einstein College Of Medicine | Monoclonal antibodies against human tim-3 |
-
2019
- 2019-08-21 US US17/270,405 patent/US12134645B2/en active Active
- 2019-08-21 KR KR1020217004986A patent/KR102917630B1/ko active Active
- 2019-08-21 AU AU2019325558A patent/AU2019325558A1/en active Pending
- 2019-08-21 CA CA3108879A patent/CA3108879A1/en active Pending
- 2019-08-21 JP JP2021502951A patent/JP7543247B2/ja active Active
- 2019-08-21 CN CN202410802960.3A patent/CN118667020A/zh active Pending
- 2019-08-21 EP EP19852182.5A patent/EP3841125A4/en active Pending
- 2019-08-21 NZ NZ770219A patent/NZ770219A/en unknown
- 2019-08-21 MX MX2020013428A patent/MX2020013428A/es unknown
- 2019-08-21 CN CN202410802940.6A patent/CN118667019A/zh active Pending
- 2019-08-21 SG SG11202012148RA patent/SG11202012148RA/en unknown
- 2019-08-21 CN CN201980037800.1A patent/CN112566936B/zh active Active
- 2019-08-21 WO PCT/US2019/047573 patent/WO2020041520A1/en not_active Ceased
- 2019-08-21 BR BR112021003018-2A patent/BR112021003018A2/pt unknown
-
2021
- 2021-02-09 IL IL280757A patent/IL280757A/en unknown
-
2024
- 2024-05-22 JP JP2024083589A patent/JP7793679B2/ja active Active
- 2024-10-02 US US18/904,972 patent/US20250034248A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534735A5 (https=) | ||
| DK2817338T3 (en) | DLL3 modulators and methods of use | |
| CN106046159B (zh) | Cd37结合分子及其免疫缀合物 | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2024119853A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| JP2021517152A5 (https=) | ||
| JP2017537082A5 (https=) | ||
| CN112105644B (zh) | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 | |
| AU2019325558A1 (en) | Monoclonal antibodies against human tim-3 | |
| CN111902156B (zh) | 人pd-l2抗体及其使用方法 | |
| CN118451106A (zh) | Claudin 18.2拮抗剂和PD-1/PD-L1轴抑制剂的组合疗法 | |
| US20250042980A1 (en) | Complement factor h antibodies | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP2021511387A5 (https=) | ||
| JPWO2020041520A5 (https=) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| CN117396508A (zh) | 用于治疗和预防与avb8整合素相关的疾病的组合物和方法 | |
| CA3173257A1 (en) | C19 c38 bispecific antibodies | |
| JP2022539344A (ja) | 抗ｃｅａ抗体及びその応用 | |
| JPWO2019175885A5 (https=) | ||
| CN116284407A (zh) | 一种抗gucy2c抗体或其抗原结合片段及其用途 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| CN113597432B (zh) | 抗EpCAM抗体及其应用 |